Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 3,230	$ 12,757
General and administrative	3,826	9,106
Intangible asset impairment charge	5,900	0
Total operating expenses	12,956	21,863
Loss from operations	(12,956)	(21,863)
Interest income	700	72
Other income (expense) net	(246)	150
Net loss before income tax benefit	(12,502)	(21,641)
Income tax benefit	248	0
Net loss	(12,254)	(21,641)
Other comprehensive income (loss):
Foreign currency translation adjustments	92	(114)
Unrealized gain (loss) on available for sales securities	235	(313)
Total comprehensive loss	$ (11,927)	$ (22,068)
Net loss per share - basic	$ (0.34)	$ (0.72)
Net loss per share - diluted	$ (0.34)	$ (0.72)
Weighted average shares of common stock outstanding - basic	35,855,200	30,134,445
Weighted average shares of common stock outstanding - diluted	35,855,200	30,134,445